274 related articles for article (PubMed ID: 32061922)
21. Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.
Morgan SJ; Neumann S; Marcus-Samuels B; Gershengorn MC
Thyroid; 2016 Dec; 26(12):1794-1803. PubMed ID: 27638195
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
23. Future Prospects for the Treatment of Graves' Hyperthyroidism and Eye Disease.
Neumann S; Place RF; Krieger CC; Gershengorn MC
Horm Metab Res; 2015 Sep; 47(10):789-96. PubMed ID: 26197854
[TBL] [Abstract][Full Text] [Related]
24. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
25. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
[TBL] [Abstract][Full Text] [Related]
26. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.
Varewijck AJ; Boelen A; Lamberts SW; Fliers E; Hofland LJ; Wiersinga WM; Janssen JA
J Clin Endocrinol Metab; 2013 Feb; 98(2):769-76. PubMed ID: 23295466
[TBL] [Abstract][Full Text] [Related]
27. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
28. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
29. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
31. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
[TBL] [Abstract][Full Text] [Related]
32. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
33. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
34. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
35. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
36. Thyrotropin receptor antagonists and inverse agonists, and their potential application to thyroid diseases.
Nagayama Y; Nishihara E
Endocr J; 2022 Nov; 69(11):1285-1293. PubMed ID: 36171093
[TBL] [Abstract][Full Text] [Related]
37. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.
Sanders J; Evans M; Betterle C; Sanders P; Bhardwaja A; Young S; Roberts E; Wilmot J; Richards T; Kiddie A; Small K; Platt H; Summerhayes S; Harris R; Reeve M; Coco G; Zanchetta R; Chen S; Furmaniak J; Smith BR
Thyroid; 2008 Jul; 18(7):735-46. PubMed ID: 18631002
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.
van Koppen CJ; de Gooyer ME; Karstens WJ; Plate R; Conti PG; van Achterberg TA; van Amstel MG; Brands JH; Wat J; Berg RJ; Lane JR; Miltenburg AM; Timmers CM
Br J Pharmacol; 2012 Apr; 165(7):2314-24. PubMed ID: 22014107
[TBL] [Abstract][Full Text] [Related]
39. TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.
Kahaly GJ; Diana T; Olivo PD
Endocr Pract; 2020 Jan; 26(1):97-106. PubMed ID: 32022598
[No Abstract] [Full Text] [Related]
40. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
